SIOP shared a post on LinkedIn:
“A major milestone for children with cancer in Europe.
On April 21, 2026, a central European market authorization was delivered for Ojemda (tovorafenib) for the treatment of paediatric low-grade glioma – the most common brain tumor in children and adolescents.
In addition, last week, the European Commission published the first ever Joint Clinical Assessment (JCA) report under the new EU HTA Regulation for Ojemda.
For the very first time in Europe, all Health Technology Assessment (HTA) bodies assessed together the clinical value of this new targeted therapy for young patients.
Joint Clinical Assessment report on tovorafenib (Ojemda)
This HTA evaluation report was available just a few weeks after the EU marketing authorization. This is a major milestone in the implementation of the new regulatory framework regarding patients access to innovative therapies.
However, Ojemda is not yet available for all children and adolescents in the EU. The next steps will be authorization in each Member State and decision on price and reimbursement at the national level.
As a member of the EU HTA Stakeholder Network, SIOPE is proud to have contributed expertise supporting the Joint Clinical Assessment of this new paediatric cancer medicine. We remain committed to helping ensure rapid and equitable access to innovative treatments for all children and adolescents with cancer across Europe.
Together, we are advancing access to innovation for children and adolescents with cancer across Europe.”
Other articles about SIOP on OncoDaily.